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Introduction
Bronchoscopy is a safe procedure with most studies 
reporting a low complication rate between 0.08–1.7% 
(1-6). A collaborative study by the American Society of 
Gastrointestinal Endoscopy and United States Food and 
Drug Administration estimated that majority of serious 
complications and mortalities during endoscopy procedures 
occur in the patients with preexisting cardiopulmonary 
diseases (7). Arrhythmias constitute a significant percent 
of the cardiovascular complications and have largely been 
attributed to premedication, procedural anesthesia, hypoxia, 
abnormal autonomic activity and myocardial ischemia. 
Cardiac implantable electronic devices (CIEDs) including 
permanent pacemakers (PPM), implantable cardioverter 
defibrillators (ICD) and cardiac resynchronization 
therapy (CRT) devices are used to treat various cardiac 
dysrhythmias, prevention of sudden cardiac death and 
for treatment of heart failure (8,9). Trends of device 
implantation for the CIEDs show a steady increase in the 
number of procedures being performed (10,11). Eighty-five 
percent of the patients with pacemakers have a significant 
number of comorbidities and are therefore at increased risk 
of complications even during minimally invasive endoscopic 
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procedures (12). 
Over the last two decades, interventional pulmonology (IP) 
has evolved considerably to include a range of technologies. 
Many IP modalities such as Laser, Electrocautery, Argon 
Plasma Coagulation and Electromagnetic Navigational 
Bronchoscopy generate electromagnetic field of varying 
strength and have been anecdotally associated with 
inadvertent interactions with CIEDs. Consequently, their 
safety and feasibility has been questioned in patients with 
these devices. Our goal here is to review and summarize the 
data pertaining to the management of CIED related issues 
in patients being considered for these interventions.
Glossary of CIED terminology relevant to 
interactions with IP procedures
Pacemaker: a device capable of providing electrical 
stimulation to the heart (pacing). Contemporary pacemakers 
also detect intrinsic cardiac electrical activity (sensing).
Pacemaker types: a single chamber pacemaker has a 
single lead and could be an atrial or more commonly a 
ventricular pacemaker. A dual chamber pacemaker has leads 
both in the atrium and the ventricle.
ICD: a device capable of detecting and terminating 
ventricular tachyarrhythmias (tachycardia/fibrillation) 
by delivering a high-energy electrical shock. ICDs with 
transvenous leads in the heart also have pacing capability. 
ICDs can be single or dual chamber, or can be standalone 
entirely subcutaneous systems without any endocardial 
leads.
CRT: a pacing strategy to electrically resynchronize the 
dyssynchronous left ventricular activation that often occurs 
in the setting of left bundle branch block. This is usually 
delivered by synchronously pacing from one site within the 
right ventricle and another site on the left ventricular free 
wall often with a lead implanted in a coronary vein. CRT 
can be delivered by a device also capable of defibrillation 
(defibrillator, CRT-D), or lacking defibrillation capability 
(pacemaker, CRT-P).
Pacemaker modes: CIED programming that dictates 
pacemaker behavior. An asynchronous mode paces 
indiscriminately at the programmed rate without assessing 
for any intrinsic cardiac activity. An inhibitory mode delivers 
pacing impulses only in the absence of intrinsic cardiac 
activity faster than the programmed pacing rate. A triggered 
mode delivers a pacing impulse as a response to a sensed 
cardiac event, for example triggered or tracked ventricular 
pacing after an appropriate offset (atrioventricular delay) in 
response to intrinsic atrial activity.
Electromagnetic interference (EMI): an electrical signal 
generated by conduction, electromagnetic induction or 
electrostatic coupling from an external source that falls 
within the sensing frequency spectrum of the CIED.
Oversensing: spurious detection by CIED of a cardiac 
event in the absence of any true physiological myocardial 
electrical activation, for example inappropriate detection of 
EMI by CIED as cardiac activity.
Unipolar versus bipolar sensing: a CIED lead is in a 
bipolar configuration if the sensing circuit records between 
two relatively closely spaced electrodes close to the tip of the 
lead. In a unipolar configuration, the sensing circuit records 
between tip electrode and the CIED generator. The wide 
spacing of the sensing electrodes in a unipolar configuration 
makes it prone to oversensing EMI, as opposed to bipolar 
configuration that limits the sensing to electrical activity 
generated from the near-field myocardium.
Inhibition: suppression of pacing due to sensing of 
electrical activity. Appropriate inhibition occurs due 
to presence of intrinsic cardiac activity. Inappropriate 
inhibition can occur due to oversensing of EMI potentially 
leading to asystole in pacemaker dependent patients.
Automatic mode switch: dual chamber CIEDs are 
commonly programmed in a tracking mode to enable 
ventricular pacing after every intrinsic atrial complex so 
as to maintain atrioventricular synchrony during sinus 
rhythm. However, tracking is not desirable during atrial 
tachyarrhythmias like atrial fibrillation as this would result 
in inappropriate rapid ventricular pacing. CIEDs thus 
automatically switch to a non-tracking mode when atrial 
activity faster than a programmed cutoff (usually 150– 
200 per minute) is detected.
Noise reversion mode: in modern CIEDs, detection 
of non-physiologic high frequency EMI results in a noise 
reversion mode with asynchronous pacing to prevent 
inappropriate inhibition. Further, CIEDs may have 
algorithms to prevent inappropriate detection of ventricular 
tachyarrhythmia. Asynchronous pacing may sometimes 
induce tachyarrhythmias due to potential for pacing during 
the vulnerable period after intrinsic electrical activity (R on 
T phenomenon).
Pacemaker reset: powerful external signals may reset the 
CIED to a “power-on” basic factory preset mode stored on 
the non-volatile read-only memory.
Inappropriate shock: a shock delivered by an ICD due to 
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inappropriate detection of ventricular tachyarrhythmia due 
to oversensing. This may occur due to EMI, oversensing of 
extracardiac physiologic signals (for example diaphragmatic 
myopotentials) or CIED lead malfunction. 
Specific IP procedures
Light amplification by stimulated emission of radiation 
(LASER)
Laser was first used in medicine in the 1960’s (13-15). It is 
one of the most commonly used ablative modalities in the 
management of malignant and nonmalignant airway lesions. 
Six different types of laser systems are available today for 
medical use, ranging in wavelength between 516–10,600 nm 
and in penetration between 0.23–10 mm (16). Neodymium-
Yttrium, Aluminum, Garnet (Nd-YAG) laser, with the 
wavelength of 1,064 nm, is the most commonly used laser 
bronchoscopically. The coagulation effect and cutting effect 
of individual laser systems determines their suitability for the 
procedure being planned. Hemorrhage, endobronchial fire, 
pneumothorax, pneumomediastinum and air embolism are 
some of the common complications. While cardiovascular 
complications have not been frequently reported, concerns 
of EMI have been raised in patients with CIEDs. In a 
study by Lister et al., the electromagnetic field strength 
around the six laser systems was measured in a laboratory 
suite and compared against the exposure limits specified by 
the cardiac device manufacturers (Medtronic and St. Jude 
Medical). Published exposure limits for the CIEDs applied 
in this study are included in Table 1. Comparative safety of 
the various laser systems during standby vs firing modes are 
summarized in Table 2. All except the CO2 and ruby lasers 
were found to generate electromagnetic field strengths 
below the permissible limits for CIEDs (17). A similar 
Brazilian in vitro study in 2015 assessed the EMI between 
the CIEDs and the endodontic laser devices and reported 
no interference caused by the endodontic TwinFlex laser 
(wavelength range 660–808 nm) device (18). Another 
study evaluating the in vitro EMI between the CIEDs and 
ophthalmic laser systems (wavelength range 193–1,064 nm) 
concluded that the CIEDs were not affected by the EMI 
generated by the ophthalmic laser systems (19). In general, 
laser appears to be safe to use from the EMI point of view 
in these in vitro studies. 
Electrocautery
Endobronchial electrocautery through flexible bronchoscope 
was first reported in early 1980’s (20-24). It is a contact 
electrosurgical ablation method in which the heat 
generated by the passage of high frequency electric current 
(radiofrequency range 100–5,000 kHz) from the probe 
to tissues causes coagulation or vaporization of the target 
tissue. There are two main configurations of electrocautery 
current delivery: monopolar and bipolar. In monopolar 
configuration, current is delivered through a cauterizing 
instrument and exits through a “ground” or “return” 
electrode placed somewhere on the patient body, usually 
the leg. Current travels through a large amount of tissue 
thereby generating significant EMI. The impact of this 
EMI on CIEDs is influenced by proximity as well as the 
orientation of the electrodes with respect to the CIED and 
its leads (25). In bipolar configuration, both the entry and 
exit electrodes are together at the tip of the cauterizing 
instrument and hence the EMI field is too small to impact 
functioning of the CIEDs. 
Most of the problems with CIEDs are reported while 
using electrocautery in the monopolar configuration (26,27). 
CIEDs can misinterpret the non-physiologic radiofrequency 
signals from EMI as pathological intracardiac events and 
consequently behave in undesirable ways. CIED behavior 
related to EMI includes inhibition of pacing, triggered 
pacing, automatic mode switching, pacemaker reset 
or reprogramming and noise reversion (28-30). ICDs 
can spuriously interpret the EMI signals as ventricular 
tachyarrhythmia and deliver inappropriate shocks (31,32). 
The high energy delivered by the electrocautery to the body 
can also damage the CIED generator and cause permanent 
malfunction. Lastly, the CIED leads can route the applied 
electrocautery energy or transmit inducted electrical energy 
through the electrode-myocardial interface potentially 
resulting in electrical cardiac stimulation or thermal injury.
Table 1 Exposure limits, as published by the CIED device 




Low frequency electric field (50/60 Hz) 6,000 V/m
Low frequency magnetic field (up to  
10 kHz)
80 A/m =100 μT
RF frequency electric field (>150 kHz) 100 V/m
Static magnetic field (DC) 5 Gauss =0.5 mT
CIED, cardiac implantable electronic devices; DC, direct current.
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Argon plasma coagulation (APC)
APC was introduced in open surgery in 1977 but first used 
endoscopically only in 1991 (33-35). It is a non-contact 
electrosurgical ablation modality used for homogeneous and 
superficial tissue coagulation. Current flows from a probe to 
the target tissue and exits through a return electrode placed 
usually on patient’s leg. Plasma in APC refers to the ionized 
argon gas jet flow. The distance between the electrode probe 
and the tissue to be treated is 2–10 mm (usually 3–5 mm). 
The plasma flows circumferentially around the electrode 
contained in a tube, and is ignited by the alternating current 
voltage (typically with amplitude of 4 kV and frequency 
of 350 kHz) through the electrode. The probe should be 
pushed 5–10 mm beyond the bronchoscope tip to avoid 
concurrent scope damage and supplemental oxygen be kept 
at ≤40% to prevent fire. Characteristics such as biochemical 
inertness, low breakdown voltage, operational simplicity 
and low cost make it a preferred intervention for endoscopic 
tissue ablation. The major advantages of APC over 
laser are in ablating distal/apical lesions and controlling 
hemoptysis (36). Complications reported with APC are gas 
embolism, airway fire, pneumomediastinum, pneumothorax, 
subcutaneous emphysema and burnt bronchoscopes. 
Due to the monopolar circuitry and high voltage use, 
APC creates high risk EMI with the CIEDs. In a study 
that measured EMI of multiple energy-based devices on 
ICD, EMI from APC was measured at 2.58±0.34 mV and 
classified as “high risk” (37). Similar to electrocautery, EMI 
can result in inhibition of pacing, device reset, inappropriate 
shock or damage to the CIED circuitry. 
Electromagnetic navigational bronchoscopy
First reported in swine models in 2003, the earliest human 
experience with Electromagnetic navigational bronchoscopy 
(ENB) was published in 2006 as an investigational 
procedure for biopsy of peripheral lung lesions (38-40). It 
entails a planning phase where a thin slice chest CT scan 
is obtained which is analyzed by the software to create a 
virtual pathway to the lesion. A board placed underneath 
the patient then creates an electromagnetic field around the 
subject that guides the sensor device (locatable guide) to the 
target lesion. 
An in vitro study measured the electromagnetic field 
used by ENB at <0.0001 tesla, similar to the earth’s gravity. 
This study failed to show any CIED dysfunction due 
to EMI caused by the ENB field. However, the human 
models used in the study were not replicative of the real-life 
circumstances (41). Because of this electromagnetic field, a 
theoretical risk of EMI causing interaction with CIEDs has 
been postulated. In fact, ENB is relatively contraindicated 
in patients with CIEDs per the 2003 CHEST guidelines for 
IP procedures (42). 
Basic principles of management
General considerations
The current guidelines and consensus statements 
on the management of CIEDs are mostly based on 
case reports and small case series (42-45). Since no 
randomized controlled trials have addressed EMI in 
Table 2 Summary of maximum recorded electric and magnetic field strengths for individual laser types, expressed as the nearest percentage point 
of the exposure limits published by the device manufacturers
Laser types
Low frequency Radiofrequency Direct current
EF MF EF MF
Standby Firing Standby Firing Standby Firing Standby Firing
Alexandrite laser 3 5 13 16 2 1 0 0
CO2 laser 19 22 55 119 26 18 136 117
Intense pulsed light 1 1 12 4 3 2 0 0
Nd:YAG laser 0 0 22 18 22 22 0 0
Pulsed dye laser 0 0 13 17 1 1 0 0
Ruby laser 21 21 6.4 206 0 0 94 105
EF, electric field; MF, magnetic field.
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patients with CIED, many recommendations are based 
solely on expert opinion. All the guidelines unequivocally 
stress on individualized management for each patient 
depending on their comorbidities and risk factors. The 
most important aspect of pre-procedure management is 
an active communication between the procedure team 
(bronchoscopist, anesthesiologist and the periprocedural 
assessment team) and the CIED team (cardiologist, cardiac 
electrophysiologist and the device nurses and staff).
Although not always necessary, when needed, patient 
should be scheduled for preoperative evaluation with 
sufficient time at hand for investigations and medical 
optimization as needed. Both pacemakers and ICDs should 
have been interrogated within the last 12 and 6 months prior 
to the planned procedure, respectively. The Heart Rhythm 
Society/American Society of Anesthesiologists consensus 
statement strongly recommends that patient’s primary 
CIED team provides recommendations on periprocedural 
management. If that is not feasible, the on-site CIED team 
provides the care in collaboration with the bronchoscopist. 
Industry-employed al l ied professions are not the 
appropriate personnel to manage CIED in this situation as 
it is considered well beyond their scope of practice (46). The 
bronchoscopist should work with the CIED team to clearly 
identify the procedure type as well as the associated EMI 
risk. Procedural aspects such as anatomic location, patient 
position, monopolar cautery use, other potential sources of 
EMI, plan or risk for cardioversion/defibrillation, procedure 
setting (endoscopy suite vs operating room), post-procedure 
disposition (inpatient admission vs same-day discharge) and 
potential extraordinary circumstances (excessive bleeding 
risk, procedural field being too close to the CIED, etc.) 
should be discussed in detail with the CIED team. The 
CIED team in turn provides a prescription to the procedure 
team for periprocedural management of the CIED. General 
principles that underscore this prescription as per the 
HRS/ASA guidelines include: (I) ICD sensing deactivation 
is not mandatory; (II) even in pacemaker dependent 
patients, changing to asynchronous mode is not always 
necessary; (III) when required, pacemakers may be rendered 
asynchronous by reprogramming or by placing a magnet 
on the pulse generator (latter works for ICDs as well); 
(IV) a universal indication for deactivating ICD sensing is 
while using monopolar electrocautery or above-umbilicus 
radiofrequency ablation; and (V) no reprogramming is 
needed in below-umbilicus use of electrocautery. The last 
recommendation is irrelevant for bronchoscopists due to 
the obvious spatial consideration.
Periprocedural risks
The prime risk of EMI with pacemakers is the cessation 
of pacing in a pacemaker-dependent patient. With ICDs, 
anti-tachycardia pacing (ATP) or shock administration is 
the main concern. In CIEDs with a rate response using an 
electrical impedance sensor, inappropriate rapid pacing may 
occur. In general, bipolar electrosurgery is not associated 
with significant EMI causing device malfunction. The HRS/
ASA guidelines identify the following potential behaviors 
with other modalities: oversensing (with consequent 
inhibition of pacing or inappropriate ICD therapies), device 
reset, pulse generator damage, and pacing at upper rate 
behavior by the impendence based rate-response systems. 
Four factors mainly determine the likelihood and severity 
of these adverse events: site of surgery, underlying cardiac 
rhythm, type and programming of the CIED and type 
of the equipment generating the EMI. In general, the 
interference decreases as the distance of the procedure from 
the CIED increases. The largest case series to date showed 
that the EMI-CIED interaction occurred only when the 
distance was <8 cm. The underlying cardiac rhythm is 
important in that only those patients who are completely 
pacemaker dependent are at risk of severe bradycardia or 
asystole. EMI lasting <5 seconds in non-dependent patients 
may cause minor pacing issues but is unlikely to cause 
asystole. 
Basics of magnet use
All CIEDs are fitted with a reed switch consisting of two 
magnetic metal strips. These strips are normally placed 
apart in glass capsules but are activated and come in contact 
when a magnetic field is applied. This contact causes a 
sudden voltage change that is detected by the sensing 
amplifier which changes the pacing to asynchronous 
mode in a pacemaker and for an ICD, prevents detection 
of ventricular tachyarrhythmia episodes (and thereby 
administration of shock) during malignant arrhythmias, 
though magnet response may be programmable in different 
CIEDs (47). Most industry-provided magnets have the 
field strength of >90 Gauss (minimum required strength: 
>10 Gauss). The CIED team may recommend either using 
the magnet or reprogramming the device but these two 
must not be considered interchangeable. Using a magnet is 
advantageous in situations wherein spontaneous malignant 
tachyarrhythmia occur. As soon as the magnet is removed, 
the device detects the malignant rhythm and delivers 
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appropriate therapeutic intervention as programmed. Using 
the magnet also eliminates the risk to the patients posed by 
inadvertent failure of the CIED team to revert the device 
back to the original therapeutic settings (48). In a database-
based evaluation of ICD patients between 1996 and 2003, 
11 ICDs were deactivated (3 after surgery) among the 212 
reported deaths (49).
Intra-procedural management 
It is universally agreed that all patients with CIEDs 
undergoing procedures generating electromagnetic field 
should be on continuous cardiac monitoring during the 
procedure (43,50). The ECG monitor being used should 
have a pacing mode capable of recognizing the pacing 
stimulus. External defibrillators must be available for use 
in the procedure room. High risk patients may be better 
served with the defibrillation pads placed prophylactically 
before initiating the procedure. Additionally, hemodynamics 
should be monitored using plethysmographic or arterial 
pressure monitoring for all these patients. 
A key determinant of pacemaker management strategy 
is patient’s pacemaker dependence. As would be expected, 
pacemaker-dependent patients (by definition, patients likely 
to suffer from asystole or severe bradycardia in the absence 
of pacemaker pacing) are at the highest risk of harm. While 
patients that are not pacemaker dependent may do well 
without any programming change, asynchronous pacing in 
pacemaker dependent patients either by magnet application 
or by reprogramming the mode should be considered if the 
pulse generator is accessible. Similarly, for patients with 
ICD, anti-tachycardia therapy/shock is inhibited by the 
application of the magnet or pre-procedure reprogramming. 
Inactivating the minute ventilation sensors could also be 
considered to negate the effects of rate responsive pacing. 
For patients who need central venous catheter placement 
using the Seldinger technique, one must be careful inserting 
the guidewire in the heart especially for the newly placed 
CIEDs due to risk of mechanical interaction with the CIED 
leads that may result in lead dislodgement. 
Whenever feasible, bipolar electrocautery probes should 
be preferred as the closely placed electrodes cause very 
small electromagnetic field and little interaction with the 
CIEDs. Monopolar configuration causes large EMI and 
should be avoided. When monopolar electrocautery or 
APC is used, the return or exit electrode should be placed 
such that the path of the current is farthest possible from 
the CIED. The incidence of EMI decreases as the distance 
of the current from the CIED increases, and in one large 
series was reported only when the distance of electrocautery 
use was <8 cm from the CIED. For this reason, the thigh 
or leg contralateral to the CIED is the preferred location 
for placement of the exit electrode. The incidence of 
clinically significant EMI is also directly proportional to the 
duration and strength of electrical energy used. Short bursts 
(preferably <5 seconds with 5-second pauses) of lowest 
strength clinically effective energy are therefore preferred.
Laser therapy creates weaker electromagnetic fields. 
Many different type of lasers have been shown to generate 
lower EMI than the permissible threshold for CIEDs. 
Barring the CO2 and ruby lasers (which are rarely used 
now), their use could be considered safe in these patients. 
Although relatively contraindicated per the current 
CHEST guidelines, ENB procedures generate low-strength 
electromagnetic field akin to the earth’s gravitational field. A 
prospective case series published in 2013 did not report any 
arrhythmia or disruption of CIED functions in 24 patients 
who underwent ENB (51). Another prospective series from 
Italy enrolled 13 patients with ICD undergoing ENB and 
did not report any electromagnetic noise detection. When 
ventricular tachyarrhythmia was induced as a part of the 
study protocol, it was promptly detected and treated by 
the ICDs as programmed (52). Of courses, these papers 
were published a decade later and did not contribute to the 
CHEST 2003 guidelines.
Post-procedural management
The HRS/ASA expert consensus statement recommends 
post-procedure CIED interrogation before moving the 
patients from a cardiac monitored environment in the 
following scenarios: CIEDs were re-programmed prior to 
the procedure; surgeries with serious hemodynamic risks 
like cardiac or vascular surgeries; significant intraprocedural 
events including hemodynamic compromise, cardiac arrest, 
ventricular tachycardia, cardiopulmonary resuscitation, 
temporary pacing or external defibrillation; site of EMI 
exposure above the umbilicus; high intensity EMI exposure 
that poses greater risk to the CIED function (e.g., 
external cardioversion or radiofrequency ablation); and, 
in patients with logistical barriers to a reliable follow-up 
and device evaluation within 1 month from the procedure. 
Regardless of whether monopolar or bipolar probe was 
used, all bronchoscopy procedures with potential for 
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EMI generation would qualify for post-procedure CIED 
interrogation by geographically being located above the 
umbilicus. It is imperative to ensure that the devices that 
were re-programmed before the procedure must be reverted 
to their pre-procedure sensing and therapeutic thresholds. 
The management strategies for the various CIEDs are 
summarized in Table 3. 
Conclusions
With the broadening inclusion criteria for patients who 
might benefit from cardiac implantable devices, the 
exposure of interventional pulmonologists to these devices 
is inevitable and ever-growing. Certain IP procedures like 
electrocautery and APC do create significant EMI and 
hence, a systematic approach to the patients with CIEDs 
undergoing these procedures is warranted. Procedures 
like laser and electromagnetic navigation bronchoscopy 
conventionally raised concerns of significant EMI but 
have been reported to be safe lately, as reviewed above. 
The existing CHEST 2003 guidelines for IP procedures 
mention ENB as relatively contraindicated in patients with 
cardiac implantable devices. However, recent literature on 
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